Source: Africa Oil.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Africa Oil (AOI) has repurchased 321,790 shares from January 23 to January 27, 2023
  • The company will cancel all repurchased shares
  • Repurchases under the program to date total 18,876,980 shares of a maximum of 40,482,356
  • Africa Oil is a Canadian oil and gas company producing and developing assets in Nigeria, Kenya and Guyana
  • Africa Oil (AOI) opened with a loss of 2.47 per cent, trading at $2.76 per share

Africa Oil (AOI) has repurchased 321,790 shares from January 23 to January 27, 2023.

This includes 115,100 shares on the TSX and/or alternative Canadian trading systems through Scotia Capital, as well as 206,690 shares on Nasdaq Stockholm through Pareto Securities.

The company will cancel all repurchased shares.

During the same period, Africa Oil cancelled 745,100 common shares repurchased under the ongoing normal course issuer bid.

Repurchases under the program to date total 18,876,980 shares of a maximum of 40,482,356.

Africa Oil is a Canadian oil and gas company producing and developing assets in Nigeria, Kenya and Guyana.

Africa Oil (AOI) opened with a loss of 2.47 per cent, trading at $2.76 per share.


More From The Market Herald

" ParcelPal (CSE:PKG) relaunches a new and improved mobile application

ParcelPal Logistics (PKG) will relaunch its mobile delivery application on a rolling basis over the coming months.

" Puma Exploration (TSXV:PUMA) confirms mineralization

Puma Exploration (PUMA) is confirming mineralization at its Williams Brook Gold Project in Northern New Brunswick.
Flying Nickel Mining

" Flying Nickel (TSXV:FLYN) confirms platinum, palladium, gold mineralization

Flying Nickel Mining (FLYN) is confirming, it uncovered gold mineralization from the most-recent drill program on its Minago Nickel PGM Project.

" NervGen Pharma (TSXV:NGEN) releases year-end operational highlights

NervGen Pharma (NGEN) reports 2022 year-end operational highlights and looks to start a phase 1b/2a clinical trial in Q3 2023.